Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Decision-Making in Gynaecological Oncology Multidisciplinary Team Meetings: A Cross-Sectional, Observational Study of Ovarian Cancer Cases.

Scott R, Hawarden A, Russell B, Edmondson RJ.

Oncol Res Treat. 2019 Nov 19:1-6. doi: 10.1159/000504260. [Epub ahead of print]

PMID:
31743932
2.

Exploiting Correlations between Protein Abundance and the Functional Status of saeRS and sarA To Identify Virulence Factors of Potential Importance in the Pathogenesis of Staphylococcus aureus Osteomyelitis.

Ramirez AM, Byrum SD, Beenken KE, Washam C, Edmondson RD, Mackintosh SG, Spencer HJ, Tackett AJ, Smeltzer MS.

ACS Infect Dis. 2019 Nov 26. doi: 10.1021/acsinfecdis.9b00291. [Epub ahead of print]

PMID:
31722523
3.

PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation.

Ren Z, Ahn JH, Liu H, Tsai YH, Bhanu NV, Koss B, Allison DF, Ma A, Storey AJ, Wang P, Mackintosh SG, Edmondson RD, Groen RWJ, Martens AC, Garcia BA, Tackett AJ, Jin J, Cai L, Zheng D, Wang GG.

Blood. 2019 Oct 3;134(14):1176-1189. doi: 10.1182/blood.2019000578. Epub 2019 Aug 5.

PMID:
31383640
4.

Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.

Mileshkin L, Edmondson R, O'Connell RL, Sjoquist KM, Andrews J, Jyothirmayi R, Beale P, Bonaventura T, Goh J, Hall M, Clamp A, Green J, Lord R, Amant F, Alexander L, Carty K, Paul J, Scurry J, Millan D, Nottley S, Friedlander M; PARAGON study group.

Gynecol Oncol. 2019 Jul;154(1):29-37. doi: 10.1016/j.ygyno.2019.05.007. Epub 2019 May 23.

PMID:
31130288
5.

Epithelial ovarian cancer risk: A review of the current genetic landscape.

Flaum N, Crosbie EJ, Edmondson RJ, Smith MJ, Evans DG.

Clin Genet. 2019 May 16. doi: 10.1111/cge.13566. [Epub ahead of print] Review.

PMID:
31099061
6.

Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.

Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Freeman S, Moore L, Jimenez-Linan M, Paul J, Brenton JD, McNeish IA; BriTROC investigators.

Br J Cancer. 2019 Apr;120(8):868. doi: 10.1038/s41416-019-0433-6.

7.

Proteomic characterization of the arsenic response locus in S. cerevisiae.

West KL, Byrum SD, Mackintosh SG, Edmondson RD, Taverna SD, Tackett AJ.

Epigenetics. 2019 Feb;14(2):130-145. doi: 10.1080/15592294.2019.1580110. Epub 2019 Mar 1.

PMID:
30739529
8.

Metaproteomics reveals potential mechanisms by which dietary resistant starch supplementation attenuates chronic kidney disease progression in rats.

Zybailov BL, Glazko GV, Rahmatallah Y, Andreyev DS, McElroy T, Karaduta O, Byrum SD, Orr L, Tackett AJ, Mackintosh SG, Edmondson RD, Kieffer DA, Martin RJ, Adams SH, Vaziri ND, Arthur JM.

PLoS One. 2019 Jan 30;14(1):e0199274. doi: 10.1371/journal.pone.0199274. eCollection 2019.

9.

Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases.

Morgan RD, Burghel GJ, Flaum N, Bulman M, Clamp AR, Hasan J, Mitchell CL, Schlecht H, Woodward ER, Lallo FI, Crosbie EJ, Edmondson RJ, Wallace AJ, Jayson GC, Evans DGR.

J Med Genet. 2019 May;56(5):301-307. doi: 10.1136/jmedgenet-2018-105792. Epub 2019 Jan 25.

PMID:
30683677
10.

Impact of surgical site infection (SSI) following gynaecological cancer surgery in the UK: a trainee-led multicentre audit and service evaluation.

O'Donnell RL, Angelopoulos G, Beirne JP, Biliatis I, Bolton H, Bradbury M, Craig E, Gajjar K, Mackintosh ML, MacNab W, Madhuri TK, McComiskey M, Myriokefalitaki E, Newton CL, Ratnavelu N, Taylor SE, Thangavelu A, Rhodes SA, Crosbie EJ, Edmondson RJ, Wan YL.

BMJ Open. 2019 Jan 24;9(1):e024853. doi: 10.1136/bmjopen-2018-024853.

11.

Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma.

Shields BD, Koss B, Taylor EM, Storey AJ, West KL, Byrum SD, Mackintosh SG, Edmondson R, Mahmoud F, Shalin SC, Tackett AJ.

Cancer Res. 2019 Mar 15;79(6):1113-1123. doi: 10.1158/0008-5472.CAN-18-1722. Epub 2019 Jan 23.

PMID:
30674537
12.

Survival of women with early-stage cervical cancer in the UK treated with minimal access and open surgery.

Martin-Hirsch P, Wood N, Whitham NL, Macdonald R, Kirwan J, Anagnostopoulos A, Hutson R, Theophilou G, Otify M, Smith M, Myriokefalitaki E, Quinland W, Mahon-Daly F, Clayton RD, Nagar H, Harley I, Dobbs S, Ratnavelu N, Kucukmetin A, Fisher AD, Tailor A, Butler-Manuel S, Madhuri K, Edmondson RJ.

BJOG. 2019 Jul;126(8):956-959. doi: 10.1111/1471-0528.15617. Epub 2019 Mar 1. No abstract available.

PMID:
30658010
13.

Label-Free Proteomic Approach to Characterize Protease-Dependent and -Independent Effects of sarA Inactivation on the Staphylococcus aureus Exoproteome.

Byrum SD, Loughran AJ, Beenken KE, Orr LM, Storey AJ, Mackintosh SG, Edmondson RD, Tackett AJ, Smeltzer MS.

J Proteome Res. 2018 Oct 5;17(10):3384-3395. doi: 10.1021/acs.jproteome.8b00288. Epub 2018 Sep 27.

14.

Copy number signatures and mutational processes in ovarian carcinoma.

Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley LA, Hanif A, Wilson C, Dowson S, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Paul J, Supernat A, Millan D, Hoyle A, Bryson G, Nourse C, Mincarelli L, Sanchez LN, Ylstra B, Jimenez-Linan M, Moore L, Hofmann O, Markowetz F, McNeish IA, Brenton JD.

Nat Genet. 2018 Sep;50(9):1262-1270. doi: 10.1038/s41588-018-0179-8. Epub 2018 Aug 13.

15.

Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.

Owens GL, Price MJ, Cheadle EJ, Hawkins RE, Gilham DE, Edmondson RJ.

Cancer Immunol Immunother. 2018 Oct;67(10):1519-1531. doi: 10.1007/s00262-018-2211-3. Epub 2018 Jul 23.

16.

Proteomic Analysis for Identification of Biomarkers that Predict Severe Acute Kidney Injury.

Arthur JM, Karakala N, Edmondson RD.

Nephron. 2018;140(2):129-133. doi: 10.1159/000491440. Epub 2018 Jul 10. Review.

17.

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.

Auguste A, Genestie C, De Bruyn M, Adam J, Le Formal A, Drusch F, Pautier P, Crosbie EJ, MacKay H, Kitchener HC, Powell M, Pollock PM, Mileshkin L, Edmondson RJ, Nout R, Nijman HW, Creutzberg CL, Bosse T, Leary A.

Mod Pathol. 2018 Dec;31(12):1851-1861. doi: 10.1038/s41379-018-0055-1. Epub 2018 Jun 28.

18.

DNA damage repair in ovarian cancer: unlocking the heterogeneity.

Gee ME, Faraahi Z, McCormick A, Edmondson RJ.

J Ovarian Res. 2018 Jun 20;11(1):50. doi: 10.1186/s13048-018-0424-x. Review.

19.

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.

Morgan RD, Clamp AR, Evans DGR, Edmondson RJ, Jayson GC.

Cancer Chemother Pharmacol. 2018 Apr;81(4):647-658. doi: 10.1007/s00280-018-3532-9. Epub 2018 Feb 20. Review.

20.

Population-based testing of non-mucinous epithelial ovarian cancer in Scotland.

Evans DG, Edmondson R, Crosbie EJ.

BJOG. 2018 Oct;125(11):1459. doi: 10.1111/1471-0528.15174. Epub 2018 May 10. No abstract available.

21.

Interventions for weight reduction in obesity to improve survival in women with endometrial cancer.

Kitson S, Ryan N, MacKintosh ML, Edmondson R, Duffy JM, Crosbie EJ.

Cochrane Database Syst Rev. 2018 Feb 1;2:CD012513. doi: 10.1002/14651858.CD012513.pub2. Review.

22.

Thymic PTH Increases After Thyroparathyroidectomy in C57BL/KaLwRij Mice.

Zangari M, Yoo H, Shin I, Kim B, Edmondson R, Morgan GJ, Suva LJ, Yoon D.

Endocrinology. 2018 Apr 1;159(4):1561-1569. doi: 10.1210/en.2017-03083.

23.

Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.

Owens GL, Sheard VE, Kalaitsidou M, Blount D, Lad Y, Cheadle EJ, Edmondson RJ, Kooner G, Gilham DE, Harrop R.

J Immunother. 2018 Apr;41(3):130-140. doi: 10.1097/CJI.0000000000000203.

24.

The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: A prospective case control study.

Kitson SJ, Lindsay J, Sivalingam VN, Lunt M, Ryan NAJ, Edmondson RJ, Rutter MK, Crosbie EJ.

Gynecol Oncol. 2018 Jan;148(1):154-160. doi: 10.1016/j.ygyno.2017.11.019. Epub 2017 Nov 24.

25.

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.

Zanjirband M, Curtin N, Edmondson RJ, Lunec J.

Oncotarget. 2017 Jul 15;8(41):69779-69796. doi: 10.18632/oncotarget.19266. eCollection 2017 Sep 19.

26.

Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.

Edmondson RJ, Crosbie EJ, Nickkho-Amiry M, Kaufmann A, Stelloo E, Nijman HW, Leary A, Auguste A, Mileshkin L, Pollock P, MacKay HJ, Powell ME, Bosse T, Creutzberg CL, Kitchener HC.

Gynecol Oncol. 2017 Aug;146(2):327-333. doi: 10.1016/j.ygyno.2017.05.014. Epub 2017 May 13.

PMID:
28511869
27.

Functional characterisation of a novel ovarian cancer cell line, NUOC-1.

McCormick A, Earp E, Elliot K, Cuthbert G, O'Donnell R, Wilson BT, Sutton R, Leeson C, Thomas HD, Blair H, Fordham S, Lunec J, Allan J, Edmondson RJ.

Oncotarget. 2017 Apr 18;8(16):26832-26844. doi: 10.18632/oncotarget.15821.

28.

BGCS uterine cancer guidelines: Recommendations for practice.

Sundar S, Balega J, Crosbie E, Drake A, Edmondson R, Fotopoulou C, Gallos I, Ganesan R, Gupta J, Johnson N, Kitson S, Mackintosh M, Martin-Hirsch P, Miles T, Rafii S, Reed N, Rolland P, Singh K, Sivalingam V, Walther A.

Eur J Obstet Gynecol Reprod Biol. 2017 Jun;213:71-97. doi: 10.1016/j.ejogrb.2017.04.015. Epub 2017 Apr 13. Review.

PMID:
28437632
29.

Indicators of responsiveness to immune checkpoint inhibitors.

Shields BD, Mahmoud F, Taylor EM, Byrum SD, Sengupta D, Koss B, Baldini G, Ransom S, Cline K, Mackintosh SG, Edmondson RD, Shalin S, Tackett AJ.

Sci Rep. 2017 Apr 11;7(1):807. doi: 10.1038/s41598-017-01000-2.

30.

Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.

Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Freeman S, Moore L, Jimenez-Linan M, Paul J, Brenton JD, McNeish IA.

Br J Cancer. 2017 May 9;116(10):1294-1301. doi: 10.1038/bjc.2017.86. Epub 2017 Mar 30. Erratum in: Br J Cancer. 2019 Apr;120(8):868.

31.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.

Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM, du Bois A, Vergote I, Reuss A, Bacon M, Friedlander M, Gallardo-Rincon D, Joly F, Chang SJ, Ferrero AM, Edmondson RJ, Wimberger P, Maenpaa J, Gaffney D, Zang R, Okamoto A, Stuart G, Ochiai K; participants of the Fifth Ovarian Cancer Consensus Conference.

Ann Oncol. 2017 Apr 1;28(4):727-732. doi: 10.1093/annonc/mdw663.

32.

Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies.

Kitson S, Sivalingam VN, Bolton J, McVey R, Nickkho-Amiry M, Powell ME, Leary A, Nijman HW, Nout RA, Bosse T, Renehan AG, Kitchener HC, Edmondson RJ, Crosbie EJ.

Mod Pathol. 2017 Mar;30(3):459-468. doi: 10.1038/modpathol.2016.203. Epub 2016 Dec 2.

33.
34.

Working together to shape the endometrial cancer research agenda: The top ten unanswered research questions.

Wan YL, Beverley-Stevenson R, Carlisle D, Clarke S, Edmondson RJ, Glover S, Holland J, Hughes C, Kitchener HC, Kitson S, Miles T, Morley R, Morrison J, Nelson L, Powell M, Sadler L, Tomlinson A, Tylko-Hill K, Whitcombe J, Crosbie EJ.

Gynecol Oncol. 2016 Nov;143(2):287-293. doi: 10.1016/j.ygyno.2016.08.333. Epub 2016 Sep 1.

35.

Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib.

McCormick A, Donoghue P, Dixon M, O'Sullivan R, O'Donnell RL, Murray J, Kaufmann A, Curtin NJ, Edmondson RJ.

Clin Cancer Res. 2017 Apr 15;23(8):2050-2060. doi: 10.1158/1078-0432.CCR-16-0564. Epub 2016 Oct 4.

36.

Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK.

Khoja L, Nolan K, Mekki R, Milani A, Mescallado N, Ashcroft L, Hasan J, Edmondson R, Winter-Roach B, Kitchener HC, Mould T, Hutson R, Hall G, Clamp AR, Perren T, Ledermann J, Jayson GC.

Clin Oncol (R Coll Radiol). 2016 Dec;28(12):760-765. doi: 10.1016/j.clon.2016.06.011. Epub 2016 Jul 9.

37.

Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity.

O'Donnell RL, Kaufmann A, Woodhouse L, McCormick A, Cross PA, Edmondson RJ, Curtin NJ.

Int J Gynecol Cancer. 2016 Jul;26(6):1004-1011. doi: 10.1097/IGC.0000000000000745.

PMID:
30814168
38.

Influence of Matrices on 3D-Cultured Prostate Cancer Cells' Drug Response and Expression of Drug-Action Associated Proteins.

Edmondson R, Adcock AF, Yang L.

PLoS One. 2016 Jun 28;11(6):e0158116. doi: 10.1371/journal.pone.0158116. eCollection 2016.

39.

Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity.

O'Donnell RL, Kaufmann A, Woodhouse L, McCormick A, Cross PA, Edmondson RJ, Curtin NJ.

Int J Gynecol Cancer. 2016 Jul;26(6):1004-11. doi: 10.1097/IGC.0000000000000745.

PMID:
27327149
40.

Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination.

Coleman HN, Greenfield WW, Stratton SL, Vaughn R, Kieber A, Moerman-Herzog AM, Spencer HJ, Hitt WC, Quick CM, Hutchins LF, Mackintosh SG, Edmondson RD, Erickson SW, Nakagawa M.

Cancer Immunol Immunother. 2016 May;65(5):563-73. doi: 10.1007/s00262-016-1821-x. Epub 2016 Mar 15.

41.

Phosphatase and Tensin Homolog Is a Potential Target for Ovarian Cancer Sensitization to Cytotoxic Agents.

McCormick A, Earp E, Leeson C, Dixon M, O'Donnell R, Kaufmann A, Edmondson RJ.

Int J Gynecol Cancer. 2016 May;26(4):632-9. doi: 10.1097/IGC.0000000000000657.

PMID:
26905328
42.

Should we worry about obesity in our ovarian cancer patients, too?

Sawan S, Edmondson RJ.

BJOG. 2016 Jan;123(2):309. doi: 10.1111/1471-0528.13773. No abstract available.

43.

Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.

Van Gool IC, Stelloo E, Nout RA, Nijman HW, Edmondson RJ, Church DN, MacKay HJ, Leary A, Powell ME, Mileshkin L, Creutzberg CL, Smit VT, Bosse T.

Mod Pathol. 2016 Feb;29(2):174-81. doi: 10.1038/modpathol.2015.147. Epub 2016 Jan 8.

44.

Hormone replacement therapy after treatment for a gynaecological malignancy.

O'Donnell RL, Clement KM, Edmondson RJ.

Curr Opin Obstet Gynecol. 2016 Feb;28(1):32-41. doi: 10.1097/GCO.0000000000000238. Review.

PMID:
26626038
45.

Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.

Bam R, Khan S, Ling W, Randal SS, Li X, Barlogie B, Edmondson R, Yaccoby S.

BMC Cancer. 2015 Nov 6;15:864. doi: 10.1186/s12885-015-1892-7.

46.

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR.

Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. Review.

47.

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.

Middleton FK, Patterson MJ, Elstob CJ, Fordham S, Herriott A, Wade MA, McCormick A, Edmondson R, May FE, Allan JM, Pollard JR, Curtin NJ.

Oncotarget. 2015 Oct 20;6(32):32396-409. doi: 10.18632/oncotarget.6136.

48.

A conserved Polϵ binding module in Ctf18-RFC is required for S-phase checkpoint activation downstream of Mec1.

García-Rodríguez LJ, De Piccoli G, Marchesi V, Jones RC, Edmondson RD, Labib K.

Nucleic Acids Res. 2015 Oct 15;43(18):8830-8. doi: 10.1093/nar/gkv799. Epub 2015 Aug 6.

49.

Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters.

Versluis MA, de Jong RA, Plat A, Bosse T, Smit VT, Mackay H, Powell M, Leary A, Mileshkin L, Kitchener HC, Crosbie EJ, Edmondson RJ, Creutzberg CL, Hollema H, Daemen T, de Bock GH, Nijman HW.

Br J Cancer. 2015 Sep 1;113(5):786-93. doi: 10.1038/bjc.2015.268. Epub 2015 Jul 28.

50.

High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers.

Dent BM, Ogle LF, O'Donnell RL, Hayes N, Malik U, Curtin NJ, Boddy AV, Plummer ER, Edmondson RJ, Reeves HL, May FE, Jamieson D.

Int J Cancer. 2016 Jan 1;138(1):206-16. doi: 10.1002/ijc.29680. Epub 2015 Aug 19.

Supplemental Content

Loading ...
Support Center